Joel Greenblatt's TVTX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 28,377 shares of Travere Therapeutics, Inc. (TVTX) worth $843,081, representing 0.00% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Joel Greenblatt has maintained this position in TVTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 28,241 shares. Largest reduction occurred in Q1 2026, reducing 27,607 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Travere Therapeutics (TVTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Travere Therapeutics (TVTX) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -27,607 | Reduce 49.31% | 28,377 | $29.71 |
| Q4 2025 | +28,241 | Add 101.80% | 55,984 | $38.21 |
| Q3 2025 | +27,743 | New Buy | 27,743 | $23.90 |
Joel Greenblatt's Travere Therapeutics Investment FAQs
Joel Greenblatt first purchased Travere Therapeutics, Inc. (TVTX) in Q3 2025, acquiring 27,743 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Travere Therapeutics, Inc. (TVTX) for 3 quarters since Q3 2025.
Joel Greenblatt's largest addition to Travere Therapeutics, Inc. (TVTX) was in Q4 2025, adding 55,984 shares worth $2.14 M.
According to the latest 13F filing for Q1 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 28,377 shares of Travere Therapeutics, Inc. (TVTX), valued at approximately $843,081.
As of the Q1 2026 filing, Travere Therapeutics, Inc. (TVTX) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Travere Therapeutics, Inc. (TVTX) was 55,984 shares, as reported at the end of Q4 2025.